linjc16/ctgov huggingface dataset:
Signs and Symptoms Associated With Molecular Defects in Genetically Inherited Heart Disease

Study Overview
=================
Brief Summary
-----------------
Genetically inherited heart diseases (familial cardiopathies) are conditions affecting the heart passed on to family members by abnormalities in genetic information. These conditions are responsible for many heart related deaths and illnesses. Researchers are interested in learning more about the specific genetic abnormalities causing heart diseases. In addition, they would like to find out how these abnormal genes can contribute to the development of other medical problems. In order to do this, researchers plan to study patients and family members of patients diagnosed with genetically inherited heart disease. Those people participating in the study will undergo a variety of tests including blood tests, echocardiograms, and magnetic resonance imaging studies (MRI). These tests will be used to help researchers find the genetic problem causing the familial cardiopathy. Researchers hope that the information gathered from this study can be used to develop better medical care through early diagnosis, management, and treatment plans.

Detailed Description
-----------------
Familial cardiomyopathies (FC) are important cardiovascular causes of morbidity and mortality that demonstrate both allelic and non-allelic genetic heterogeneity. We propose to perform genetic studies to determine novel molecular causes of FC and to describe their clinical correlates. This will permit: (1) pre-symptomatic diagnosis; (2) definition of cardiac phenotype, disease penetrance; (3) natural history; (4) study of abnormal physiology that is a consequence of the molecular defect; (5) elucidation of specific mechanisms of arrythmias and sudden death; and (6) demonstration and characterization of skeletal muscle involvement.

Official Title
-----------------
Clinical Correlates of Molecular Defects in Familial Cardiomyopathy

Conditions
-----------------
Congenital Heart Defect

Participation Criteria
=================
Eligibility Criteria
-----------------
INCLUSION AND EXCLUSION CRITERIA The subjects will consist of family members who may have inherited FC and spouses that may help in the linkage studies. Family members or spouses who do not wish to participate in the research protocol will be excluded from the study.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Genetics, Cardiac Diseases, Cardiac Hypertrophy, Sudden Death, Arrhythmias
Linkage and Identification of (a) Candidate Gene(s) for Tooth Disorders

Study Overview
=================
Brief Summary
-----------------
The congenital absence of teeth, commonly referred to as hypodontia or tooth agenesis, is a common developmental anomaly of human dentition that affects approximately 20% of the population. Although new genetic and molecular approaches in humans and mice have increased our understanding of the molecules that control tooth patterning (number, position, shape and size), the precise nature of the genes involved in hypodontia in humans is poorly understood. Hence, understanding the molecular basis for missing teeth is an issue of paramount importance that is both timely and significant to the practice of dentistry. So far, only two genes have been associated with non-syndromic familial tooth agenesis: MSX1 and PAX9. Substitution mutations in the homeodomain region of MSX1 were linked to premolar agenesis while an insertion mutation in the paired box domain of PAX9 was shown to be responsible for molar oligodontia. The long-term goals of this research are to elucidate the molecular pathology of human tooth agenesis, in particular, to evaluate whether genes other than MSX1 and PAX9 (locus heterogeneity) are involved. Alternatively, as in the case of MSX1, it will be interesting to know whether allelic variations, different mutations in these genes, are associated with tooth agenesis. We propose to study a potentially large kindred that report the developmental absence of several posterior teeth. The fundamental hypothesis to be tested states that the gene responsible for the congenital absence of molar teeth in this kindred is a critical element in the genesis of molars. The specific goals are to perform linkage analysis followed by direct sequencing of PCR products to identify the gene and to characterize the nature of the underlying defect. Identifying the underlying gene defect in this family affected by tooth agenesis will add new knowledge to our understanding of the pathogenesis of this defect and will provide the basis for future studies.

Official Title
-----------------
Linkage and Identification of (a) Candidate Gene(s) for Tooth Disorders

Conditions
-----------------
Anodontia

Participation Criteria
=================
Eligibility Criteria
-----------------
Patients affected with non-syndromic tooth agenesis and non-affected family members

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Human tooth agenesis
10 Years Cardiovascular Risk Score Among Primary Health Care Centre Attendees, Assiut Governorate.

Study Overview
=================
Brief Summary
-----------------
The study aim to assess cardiovascular risk score among patients of AlHadary primary health care centre in Waldeya, Assiut governorate. And to determine the awareness about cardiovascular risk among these patients as well.

Detailed Description
-----------------
An analytical, cross-sectional study will be conducted in a primary health care center in Assiut governorate. Aiming to assess cardiovascular risk among attendees of the center and determine the awareness about cardiovascular risk among them.

Official Title
-----------------
10 Years Cardiovascular Risk Score Among Primary Health Care Centre Attendees, Assiut Governorate.

Conditions
-----------------
Cardiovascular Risk Score

Intervention / Treatment
-----------------
* Other: Framingham study cardiovascular disease 10-years risk assessment score


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male 30-65 years old, or female 40-70 years old. Exclusion Criteria: History of ischemic heart disease, stroke, transitory ischemic attack (TIA) or peripheral artery disease (PAD) in electronic health record. History of diabetes

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Framingham study cardiovascular disease 10-years risk assessment score|A personal interview questionnaire|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The Framingham study cardiovascular disease 10 years risk assessment results | Participants will be categorized into four risk groups based on the 10 years ASCVD risk percentages. | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Total cardiovascular disease knowledge score results | will be calculated by summing the scores of respondents concerning cardiovascular disease types, heart attack symptoms, stroke symptoms and CVR factors. Total knowledge score will be 24. knowledge levels will be categorized as low knowledge, moderate knowledge and high knowledge. | 1 year |
AR vs In Person Simulation for Medical Workplace Training

Study Overview
=================
Brief Summary
-----------------
This study will evaluate the physiologic and emotional effects of an augmented reality (AR) simulation versus an in-person simulation. This is a single institution, non-inferiority, randomized controlled trial. The target enrollment will be 100 participants in each group for a total of 200 participants. One group will wear an AR headset and participate in an AR medical crisis scenario and the other group will participate in the same scenario with a traditional, mannequin based in situ simulation.

Official Title
-----------------
The Physiologic and Emotional Effects of Augmented Reality Simulation Versus In Person Simulation - A Noninferiority, Randomized Controlled Trial

Conditions
-----------------
Augmented Reality

Intervention / Treatment
-----------------
* Behavioral: Augmented Reality Headset


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hospital providers, including nurses, physician assistants, physicians, physician trainees, and other healthcare workers at Lucile Packard Children's Hospital (LPCH) and affiliated facilities who communicate with patients daily will be included Exclusion Criteria: Participants with reported severe motion sickness Nausea Seizure disorder Currently using chronotropic heart medications, such as β blockers

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Augmented Reality Enhanced Simulation (Treatment group)<br>Participants will experience augmented simulations with a holographic mixed-reality setting based on different workplace scenarios such as medical error and workplace harassment via Augmented Reality (AR) headset. | Behavioral: Augmented Reality Headset<br>* Augmented simulation of workplace-related scenarios of pre-recorded videos using the same actors<br>|
| No Intervention: Traditional In Situ Simulation (Control group)<br>Participants will experience in-person simulations of different workplace scenarios such as medical error and workplace harassment | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Parasympathetic withdrawal | Measured via respiratory sinus arrhythmia (RSA) in hertz | Duration of simulation (15-20 minutes) | 
| Sympathetic activation | Increases in skin conductance in reactivation (microsiemens) | Duration of simulation (15-20 minutes) |
Multiepitope Peptide Vaccination in Melanoma

Study Overview
=================
Brief Summary
-----------------
This trial assesses the clinical efficacy of a multiepitope peptide vaccine with GM-CSF and KLH as immunological adjuvants in stage IV melanoma patients

Official Title
-----------------
Phase II Study of Multiepitope Peptide Vaccination in Combination With Adjuvants GM-CSF and KLH in Metastatic Melanoma

Conditions
-----------------
Metastatic Melanoma

Intervention / Treatment
-----------------
* Biological: Tyrosinase, MAGE-3, GnTV


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Metastatic melanoma HLA-A1, -A2, -A24, -B44 Exclusion Criteria:

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: Tyrosinase, MAGE-3, GnTV|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical efficacy |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Immune response |  |  | 
| Safety |  |  |
Antimicrobial Drug Use and Resistant Staphylococcus Aureus

Study Overview
=================
Brief Summary
-----------------
The purpose of this investigation is to study the relationships between antimicrobial stewardship program efforts, antimicrobial drug use, and infection control efforts to the incidence rates of hospital acquired infections with Staphylococcus aureus in a sample of US academic medical center hospitals.

Detailed Description
-----------------
Hospitalized patients can become infected with a variety of microorganisms, but infections caused by Staphylococcus aureus (i.e., staph infections) are particularly common. The main strategy to reduce the number of patients infected with Staph. aureus is to decrease cross-transmission from one patient to another. In addition, increasing evidence suggests that improvements in antimicrobial drug use--promoted by hospital Antimicrobial Stewardship programs (ASPs) -- may also favorably impact rates of Staph. aureus infections. While many Staphylococcal strains remain susceptible to an old drug called methicillin (methicillin-susceptible Staph aureus, or MSSA), many Staph. aureus are methicillin-resistant (MRSA). The drug of choice for MRSA has historically been vancomycin, and vancomycin is now the most commonly prescribed antibiotic in US teaching hospitals. Vancomycin-resistant Staph. aureus (VRSA) is still uncommon, but some Staph. aureus are developing low level resistance to vancomycin. These strains are often called S. aureus with MIC creep to vancomycin (SA-MICcreep), and Staphylococcus aureus with Heterogeneous Resistance to Vancomycin (hVISA), but the epidemiology, clinical significance and risk factors for these organisms are not well described. We will survey UHC participating hospitals to learn more about these organisms, the drug and ASP related risk factors, and whether hospitals are trying to identify these organisms.

Official Title
-----------------
Antimicrobial Drug Use and Resistant Staphylococcus Aureus in a Network of Academic Medical Center Hospitals.

Conditions
-----------------
Staphylococcus Aureus

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: NA Exclusion Criteria: NA

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Association between Antimicrobial Stewardship Program and Infection Control efforts, antibacterial drug use and rates of hVISA and other resistant staphylococci. | Rates of hVISA and Staph.aureus with MIC creep to vancomycin | 2008 and 2009 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Staphylococcus aureus, Antimicrobial Stewardship, Antibacterial resistance, Vancomycin
Validation Study of Linear Quantification of CD3+ Cells in Localized Colorectal Carcinomas

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to confirm that linear quantification of CD3+ cells is a prognostic biomarker in localized colorectal carcinomas.

Detailed Description
-----------------
Adult patients of both gender who have underwent surgical resection of stage III colorectal carcinoma and randomised to receive a chemotherapy FOLFOX or FOLFOX + Cetuximab in the PETACC8 trial.

Official Title
-----------------
Biomarker Validation Study of Linear Quantification of CD3 Positive Cells in Localized Colorectal Carcinomas, Based on the Cohort of Patient Included in PETACC8 International Phase III Trial (NCT00265811)

Conditions
-----------------
Metastatic Colorectal Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient included in PETACC08 study Signed informed consent for translational study FFPE tumor sample available for CD3 staining Exclusion Criteria: - Patient who have withdrawn their consent for PETACC08 and/or for PETACC08 translational study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 74 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Arm A<br>Patients with no or low immune response (score 1 or 2) with linear quantification of CD3+ cells | |
| Arm B<br>Patients with high immune response (score 3 or 4) with linear quantification of CD3+ cells | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to Recurrence (TTR) | TTR is defined by the time between randomisation and the first event occured (Local or metastatic recurrence or death due to disease recurrence) whichever occured first or last follow-up ( Last news for patients without event (censored data)) | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall Survival (OS) | Overall survival is defined as the time from randomization to death any cause or last follow-up news (censored data). | until death | 
| Disease-Free Survival (DFS) | DFS is defined by the time between randomisation and the first event occured (Local or metastatic recurrence or second cancer or death (all causes)) whichever occured first or last follow-up ( Last news for patients without event (censored data)) | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Colon and rectum carcinoma, Immune response, Biomarker, Prognosis
Aerosolisation During Respiratory Procedures

Study Overview
=================
Brief Summary
-----------------
Currently, a major issue within respiratory medicine is undertaking procedures that generate aerosolisation with the concern of spreading infection, such as the SARS-COV-2/COVID-19 virus. It is anecdotally reported that lung function testing and positive airways pressure devices used in clinical practice are aerosol generating procedures however the data to support this is limited. With the advent of high-speed imaging systems that can capture and quantify particle size and velocity we aim to investigate the aerosol generation in routine non-invasive positive pressure respiratory procedures.

Official Title
-----------------
A Proof of Concept Study to Evaluate Aerosol Generation During Non-Invasive Positive Pressure Respiratory Procedures

Conditions
-----------------
Healthy, Respiratory Tract Infections, Lung Infection, Droplet Spread

Intervention / Treatment
-----------------
* Other: Not an interventional study


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18-80 years Healthy subjects with no active medical conditions or previous pneumothorax Cognitively and linguistically able to follow instructions given in English and provide informed consent Exclusion Criteria: Significant respiratory, cardiac or neurological conditions or previous pneumothorax Smoking history greater than 10 pack years Acute illness at the time of assessment Allergies to latex, metals or local anaesthetic agents

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Not an interventional study|No interventions are implemented. This is an observational study of respiratory droplet aerosolisation during respiratory procedures.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Characterisation of aerosolised respiratory droplets | Performed using high-speed imaging and particle size counters | 1 year |
A Study to Evaluate the Safety, Tolerability, and Effects of Anatabloc® Crème in Rosacea

Study Overview
=================
Brief Summary
-----------------
This is a multi-site, four-visit, eight-week, double-blind, randomized, vehicle-controlled, parallel-group study followed by an eight-week open-label extension to evaluate the safety, tolerability, and potential effects of Anatabloc Facial Cream. The secondary aim is to evaluate if Anatabloc Facial Cream improves the appearance of the skin in subjects with mild to moderate rosacea.

Official Title
-----------------
An Eight-Week, Multi-Site, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Trial to Evaluate the Safety, Tolerability, and Effects of Anatabloc® Crème in Subjects With Rosacea Followed by an Open-Label Extension

Conditions
-----------------
Rosacea

Intervention / Treatment
-----------------
* Other: Anatabloc Cream
* Other: Placebo Cream


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age between 25-70 years diagnosed with mild to moderate rosacea Exclusion Criteria: allergy or sensitivity to the study products or their components severe rosacea current use of glucocorticoids, anti-acne products, antibiotics, topical retinoids, or vasoactive drugs recent oral isotretinoin use current use of anatabine-containing supplements (ie. Anatabloc, Anatabloc Unflavored, CigRx)

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Anatabloc Cream<br>Twice daily use of active facial cream | Other: Anatabloc Cream<br>* subject will apply active cream topically, twice per day according to instructions<br>|
| Placebo Comparator: Placebo Cream<br>Twice daily use of placebo facial cream | Other: Placebo Cream<br>* subject will apply placebo cream topically, twice per day according to instructions<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse Effects | Collected information of the safety, tolerability and adverse events, and subjective experience related to the use of Anatabloc Cream by subjects | 8 to 16 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in the appearance of the facial skin | Change measured by comparison of questionnaire and rating scores over time | 8 to 16 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
rosacea, anatabine, Anatabloc, dermatology